Related Experiment Video

Updated: May 20, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

An update on biomarkers of heart failure in hypertensive patients

Anna Gluba1, Agata Bielecka-Dabrowa, Agata Bielecka

  • 1Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Poland.

Journal of Hypertension
|July 26, 2012
PubMed

Insights

Identifying novel biomarkers for heart failure (HF) in hypertensive patients is crucial for early intervention. This review explores potential biomarkers like serum uric acid and B-type natriuretic peptide to improve risk prediction and patient outcomes.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Hypertension Management

Background:

  • Heart failure (HF) prediction in hypertensive patients lacks sufficient sensitive and specific biomarkers.
  • Current risk stratification for hypertensive heart disease may not identify all at-risk individuals early.

Purpose of the Study:

  • To review and summarize potential biomarkers for predicting heart failure in hypertensive individuals.
  • To highlight the need for improved diagnostic tools for early intervention in hypertensive heart disease.

Main Methods:

  • Literature review of studies investigating biomarkers in hypertensive patients with heart failure.
  • Analysis of various biomarkers including serum uric acid, interleukins, natriuretic peptides, and collagen markers.

Main Results:

  • Several biomarkers such as serum uric acid (SUA), interleukins, monocyte chemoattractant protein one (MCP-1), cardiotrophin-1 (CT-1), collagen peptides (PICP, CITP, PIIINP), metalloproteinases (MMPs), B-type natriuretic peptide (BNP) and its derivatives, CA125, and cystatin C show potential.
  • Limited biomarkers currently offer incremental predictive utility over standard risk factors for HF in this population.

Conclusions:

  • Novel biomarkers are needed to enhance the early detection and risk prediction of heart failure in hypertensive patients.
  • Identifying patients who would benefit from earlier or more aggressive preventive strategies is essential for improving clinical outcomes.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...